Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status:
Completed
Trial end date:
2016-03-04
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and
tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal
hepatic function, moderate hepatic impairment and severe hepatic impairment. Participants in
the healthy control group will be matched to participants with impaired hepatic function by
gender, age (± 10 years), and body mass index (± 15%).